Live News

Sipavibart (KAVIGALE®), a recombinant human immunoglobulin (Ig)G1-based antibody, is being developed by AstraZeneca f...

Drugs

0 0

Ivarmacitinib Sulfate: First Approval

Ivarmacitinib sulfate (ivarmacitinib; 艾速达®), a selective Janus kinase 1 (JAK1) inhibitor, is bei...

Drugs

0 0

Tiratricol: First Approval

Tiratricol (Emcitate®) is an orally bioavailable small molecule being developed by Egetis Therapeutics for the treatm...

Drugs

0 0

Recaticimab: First Approval

Recaticimab (艾心安®), a humanized monoclonal immunoglobulin G1 antibody that targets proprotein co...

Drugs

0 0

Limertinib: First Approval

Limertinib (Aoyixin) is an orally available, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhi...

Drugs

0 0

Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Plecanatide is a novel guanylate cyclase-C agonist for the treatment of functional constipation (FC). Its efficacy may var...

Drugs

0 0

Fitusiran: First Approval

Haemophilia A and B are inherited bleeding disorders caused by mutations in clotting factors. Small interfering RNA therap...

Drugs

0 0

Ensifentrine Plus a Long-Acting Muscarinic Antagonist in COPD: A Trifunctional Dual Bronchodilation Perspective

Chronic obstructive pulmonary disease (COPD) management has evolved with the emergence of advanced pharmacological strateg...

Drugs

0 0

Acoltremon: First Approval

Acoltremon (TRYPTYR®) is a TRPM8 thermoreceptor agonist formulated as eye drops, which has been developed by Alcon fo...

Drugs

0 0

Senaparib: First Approval

Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated benefits in progression-free survival for first-line maint...

Drugs

0 0

Telisotuzumab Vedotin: First Approval

Telisotuzumab vedotin (telisotuzumab vedotin-tllv; EMRELIS™), an antibody-drug conjugate (ADC) directed against c-me...

Drugs

0 0

Luvometinib: First Approval

Luvometinib (复迈宁®), a highly selective orally administered mitogen-activated protein kinase kina...

Drugs

0 0

Atrasentan: First Approval

Atrasentan (VANRAFIA®), a potent, highly selective, orally administered endothelin type A (ETA) receptor antagonist, ...

Drugs

0 0

Avutometinib and Defactinib: First Approval

Avutometinib and defactinib (AVMAPKI™ FAKZYNJA™ CO-PACK) is a co-packaged rapidly accelerating fibrosarcoma (R...

Drugs

0 0

Gepotidacin: First Approval

Gepotidacin (BLUJEPA), a small molecule triazaacenaphthylene bacterial type II topoisomerase inhibitor (BTI) antibacterial...

Drugs

0 0

Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial

Sovateltide (Tycamzzi™), an endothelin-B (ET-B) receptor agonist, increases cerebral blood flow, has anti-apoptotic ...

Drugs

0 0

Fulzerasib: First Approval

Fulzerasib (Dupert®; Innovent Biologics/GenFleet Therapeutics) is an orally active small molecule inhibitor of the KR...

Drugs

0 0

A Meta-analysis Exploring the Efficacy of Neuropathic Pain Medication for Low Back Pain or Spine-Related Leg Pain: Is Efficacy Dependent on the Presence of Neuropathic Pain?

Highly variable pain mechanisms in people with low back pain or spine-related leg pain might contribute to inefficacy of n...

Drugs

0 0

The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab

The accelerated approval (AA) pathway was established by the United States Food and Drug Administration (FDA) to provide e...

Drugs

0 0

The Challenge of Treating Infections Caused by Metallo‐β‐Lactamase–Producing Gram-Negative Bacteria: A Narrative Review

Gram-negative multidrug-resistant (MDR) bacteria, including Enterobacterales, Acinetobacter baumannii, and Pseudomonas aer...

Drugs

0 0

Difficult-to-Treat Axial Spondyloarthritis: A New Challenge

Axial spondyloarthritis is a common form of chronic inflammatory rheumatic disease in adults, the treatment of which is ba...

Drugs

0 0

2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP)

Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors ...

Drugs

0 0

Odronextamab: First Approval

Odronextamab (Ordspono™), a CD20xCD3 bispecific antibody, is being developed by Regeneron Pharmaceuticals for the tr...

Drugs

0 0

Trientine Tetrahydrochloride, From Bench to Bedside: A Narrative Review

Trientine tetrahydrochloride (TETA-4HCl, Cuvrior®) is a copper chelating agent with the active moiety triethylenetetr...

Drugs

0 0

Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology

Due to the lack of a comprehensive pharmacology test set, evaluating the potential and value of large language models (LLM...

Drugs

0 0

Xeligekimab: First Approval

Xeligekimab (Jinlixi®) is a recombinant human interleukin (IL)-17A-neutralizing immunoglobulin (Ig)G4 monoclonal anti...

Drugs

0 0

Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials

The prescribing of opioids to patients for postoperative pain can lead to persistent opioid use. This review investigated ...

Drugs

0 0

Gepirone Extended-Release: First Approval

Gepirone HCL extended-release (gepirone ER; EXXUA™), an oral, selective serotonin (5HT)1A receptor agonist formulate...

Drugs

0 0

New Therapies on the Horizon for Primary Biliary Cholangitis

Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease that can progress to cirrhosis and hepatic failur...

Drugs

0 0

Zilucoplan: First Approval

Zilucoplan (Zilbrysq®) is a subcutaneously administered macrocyclic peptide inhibitor of complement component 5 (C5 i...

Drugs

0 0

Categories

Channels

SCI Abstract